HF 1884

as introduced - 93rd Legislature (2023 - 2024) Posted on 02/16/2023 01:41pm

A bill for an act
relating to health care; establishing a psychedelic medicine task force; requiring
a report.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1. new text begin PSYCHEDELIC MEDICINE TASK FORCE.
new text end

new text begin Subdivision 1. new text end

new text begin Establishment; purpose. new text end

new text begin The Psychedelic Medicine Task Force is
established to advise the legislature on the legal, medical, and policy issues associated with
the legalization of psychedelic medicine in the state.
new text end

new text begin Subd. 2. new text end

new text begin Membership; compensation. new text end

new text begin (a) The Psychedelic Medicine Task Force shall
consist of:
new text end

new text begin (1) the governor or a designee;
new text end

new text begin (2) two members of the house of representatives appointed by the speaker of the house
and two senators appointed by the president of the senate;
new text end

new text begin (3) the commissioner of health or a designee;
new text end

new text begin (4) the commissioner of public safety or a designee;
new text end

new text begin (5) the commissioner of human services or a designee;
new text end

new text begin (6) the attorney general or a designee;
new text end

new text begin (7) the executive director of the Board of Pharmacy or a designee;
new text end

new text begin (8) the commissioner of commerce or a designee; and
new text end

new text begin (9) members of the public, appointed by the governor, who have relevant knowledge
and expertise, including:
new text end

new text begin (i) two members representing Indian Tribes within the boundaries of Minnesota, one
representing the Ojibwe Tribes and one representing the Dakota Tribes;
new text end

new text begin (ii) one member with expertise in the treatment of substance use disorders;
new text end

new text begin (iii) one member with experience working in public health policy;
new text end

new text begin (iv) two veterans with treatment-resistant mental health conditions;
new text end

new text begin (v) two patients with treatment-resistant mental health conditions;
new text end

new text begin (vi) one physician with experience treating treatment-resistant mental health conditions,
including post-traumatic stress disorder;
new text end

new text begin (vii) one health care practitioner with experience in integrative medicine;
new text end

new text begin (viii) one psychologist with experience treating treatment-resistant mental health
conditions, including post-traumatic stress disorder; and
new text end

new text begin (ix) one member with demonstrable experience in the medical use of psychedelic
medicine.
new text end

new text begin (b) Members listed in paragraph (a), clauses (1) and (3) to (8), and members appointed
under paragraph (a), clause (9), may be reimbursed for expenses under Minnesota Statutes,
section 15.059, subdivision 6. Members appointed under paragraph (a), clause (2), may
receive per diem compensation from their respective bodies according to the rules of their
respective bodies.
new text end

new text begin (c) Members shall be designated or appointed to the task force by July 15, 2023.
new text end

new text begin Subd. 3. new text end

new text begin Organization. new text end

new text begin (a) The commissioner of health or the commissioner's designee
shall convene the first meeting of the task force.
new text end

new text begin (b) At the first meeting, the members of the task force shall elect a chairperson and other
officers as the members deem necessary.
new text end

new text begin (c) The first meeting of the task force shall occur by August 1, 2023. The task force shall
meet monthly or as determined by the chairperson.
new text end

new text begin Subd. 4. new text end

new text begin Staff. new text end

new text begin The commissioner of health shall provide support staff, office and meeting
space, and administrative services for the task force.
new text end

new text begin Subd. 5. new text end

new text begin Duties. new text end

new text begin The task force shall:
new text end

new text begin (1) survey existing studies in the scientific literature on the therapeutic efficacy of
psychedelic medicine in the treatment of mental health conditions, including depression,
anxiety, post-traumatic stress disorder, and bipolar disorder, and any other mental health
conditions and medical conditions for which a psychedelic medicine may provide an effective
treatment option. Psychedelic medicine may include but is not limited to the use of
3,4-methylenedioxymethamphetamine (MDMA), psilocybin, mescaline, LSD, bufotenine,
DMT, 5-MeO-DMT, 2C-B, ibogaine, salvinorin A, and ketamine;
new text end

new text begin (2) evaluate and determine whether any specific psychedelic medicine is effective in
treating any of the conditions described in clause (1);
new text end

new text begin (3) compare the efficacy of psychedelic medicine in treating the conditions described
in clause (1) with the efficacy of treatments currently used for these conditions; and
new text end

new text begin (4) develop a comprehensive plan that covers:
new text end

new text begin (i) statutory changes necessary for the legalization of psychedelic medicine;
new text end

new text begin (ii) state and local regulation of psychedelic medicine;
new text end

new text begin (iii) federal law, policy, and regulation of psychedelic medicine, with a focus on retaining
state autonomy to act without conflicting with federal law, including methods to resolve
conflicts such as seeking an administrative exemption to the federal Controlled Substances
Act under United States Code, title 21, section 822(d), and Code of Federal Regulations,
title 21, part 1307.03; seeking a judicially created exemption to the federal Controlled
Substances Act; petitioning the United States Attorney General to establish a research
program under United States Code, title 21, section 872(e); utilizing the Food and Drug
Administration's expanded access program; and utilizing authority under the federal Right
to Try Act; and
new text end

new text begin (iv) education of the public on recommendations made to the legislature and others about
necessary and appropriate actions related to the legalization of psychedelic medicine in the
state.
new text end

new text begin Subd. 6. new text end

new text begin Reports. new text end

new text begin The task force shall submit two reports to the chairs and ranking
minority members of the legislative committees with jurisdiction over health and human
services that detail the task force's findings regarding the legalization of psychedelic medicine
in the state, including the comprehensive plan developed under subdivision 5. The first
report must be submitted by February 1, 2024, and the second report must be submitted by
January 1, 2025.
new text end